Clinical leadership Medinol has a strong track record in delivering coronary stents with FDA and CE approvals, two million stents shipped globally, and in-house proprietary manufacturing. This suggests a credible platform for co-development discussions, high-trust partnerships, and potential for expanded product adoption in health systems seeking proven, in-house manufactured devices.

EluNIR opportunity EluNIR is a first-of-its-kind elastomeric drug-eluting stent with advanced delivery features (Flexx² catheter, metallic spring-tip) and favorable safety/clinical signals. This presents a clear entry point for distribution partnerships, hospital formulary alignment, and teaching-focused sales efforts to drive broader utilization in complex anatomies.

Distribution expansion Recent U.S. distribution activity with CoSo Health for EluNIR indicates openness to strategic partnerships to accelerate market access. Target distributors and IDNs with robust cardiovascular portfolios to scale geographic reach, along with joint demand-generation programs.

Growth potential Revenue scale is mid-market with a global footprint and a founder-led private company culture. This signals opportunity for value-based procurement conversations, pilot programs with hospitals, and multi-year purchasing agreements as hospitals seek reliable, innovative DES options.

Strategic focus With in-house manufacturing and a focus on cardiovascular intervention innovation, Medinol is positioned for partnerships around manufacturing efficiency, supply reliability, and joint development. Propose collaborations on next-generation DES features, equipment integration, and clinical evidence generation to differentiate offerings.